Skip to main content

Advertisement

Fig. 5 | Molecular Cancer

Fig. 5

From: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Fig. 5

Minimal toxicity of LL28 in vivo. a and c Schematic diagram of the experiment. b Changes in body weight induced by treatment with LL28 in mice. d and e The level of ALT and AST in the serum and the number of WBC and RBC in whole blood obtained from mice treated with either linsitinib and dasatinib in combination or LL28 were determined as described in the Methods section. f The blood glucose level was determined by using tail snip blood with blood glucose test strips. g The histopathological changes in liver, lung, brain, and kidney from mice treated with either linsitinib and dasatinib in combination or LL28 were evaluated by using H&E-stained section of the tissues. The representative images of H&E-stained  section of the tissues were shown. Scale bar: 20 μm. The bars represent the means ± SD; *P < 0.05 and **P < 0.01, as determined by a two-sided Student’s t-test. Con: control; L + D: linsitinib and dasatinib in combination

Back to article page